Skip to Main Content

Cytokinetics, Incorporated (NASDAQ: CYTK) Securities Fraud Class Action

View Complaint
CompanyCytokinetics, Incorporated
CourtUnited States District Court for the Northern District of California
Case Number3:25-cv-07923
JudgeHonorable Sallie Kim
Class PeriodDecember 27, 2023 through May 6, 2025
Security TypeCommon Stock

LEAD PLAINTIFF DEADLINE IS NOVEMBER 17, 2025.

If you have suffered losses and would like to discuss your rights, please fill out this form or you may contact Jonathan Naji, Esq. at (484) 270-1453 or via e-mail at info@ktmc.com.

Case Background:
A class action lawsuit was filed on behalf of those who purchased or otherwise acquired Cytokinetics, Incorporated (“Cytokinetics”) (NASDAQ: CYTK) common stock between December 27, 2023 and May 6, 2025, inclusive (the “Class Period”).

The complaint alleges that, throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material facts about the company’s business, operations, and prospects.  Specifically, Defendants misrepresented and/or failed to disclose that: (1)  Cytokinetics failed to submit a Risk Evaluation and Mitigation strategy for its New Drug Application for aficamenten, Cytokinetics’ lead drug candidate; (2) Cytokinetics’ failure to submit the foregoing could delay the timeline for the NDA submission and approval process; and (3) as a result of the foregoing, Defendants’ statements about the company’s business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.
 

What is a Lead Plaintiff?

A lead plaintiff is a representative party that acts on behalf of other class members in directing the litigation. In order to be appointed lead plaintiff, the Court must determine that the class member’s claim is typical of the claims of other class members, and that the class member will adequately represent the class. Your ability to share in any recovery is not, however, affected by the decision whether or not to serve as a lead plaintiff. Filling out the online form above or communicating with any counsel is not necessary to participate or share in any recovery achieved in this case.  Any member of the purported class may move the court to serve as a lead plaintiff through counsel of his/her choice, or may choose to do nothing and remain an inactive class member.

Complete this form with your transactions in Cytokinetics, Incorporated common stock between December 27, 2023 and May 6, 2025.

Click Here to Print PDF of this Form

SUBMIT YOUR INFORMATION
* Denotes required field
Date
# of Shares
Price per Share
Date
Principal Amount
Amount Paid
Series or CUSIP
Date
# of Contracts
Price per Contract
Exercise Price
Expiration Date
Did you purchase shares of Cytokinetics, Incorporated prior to the Class Period?
Are you a current or former employee of Cytokinetics, Incorporated ?
The submission of this form does not create an attorney-client relationship, nor an obligation on the part of Kessler Topaz or you to file a lead plaintiff motion in this matter. Any information you submit will be maintained as confidential. If Kessler Topaz, in its sole discretion, believes that you might be an appropriate lead plaintiff candidate, Kessler Topaz will contact you to discuss the matter and whether to establish an attorney client relationship. By signing this form you are authorizing us to contact you regarding this case and/or future cases.
I agree to the KTMC disclaimer
I would like to receive new case alerts by email